Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Multicentre, Randomised, Open, Controlled, Two-Parallel Group, Phase II Pilot Study to Evaluate the Efficacy and Safety of ARIXTRA for Anticoagulation of Patients With Atrial Fibrillation Undergoing Electric Cardioversion Following Transesophageal Echocardiography

Next Previous
Trial Profile

An International, Multicentre, Randomised, Open, Controlled, Two-Parallel Group, Phase II Pilot Study to Evaluate the Efficacy and Safety of ARIXTRA for Anticoagulation of Patients With Atrial Fibrillation Undergoing Electric Cardioversion Following Transesophageal Echocardiography

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fondaparinux sodium (Primary) ; Fluindione; Heparin; Phenprocoumon; Warfarin
  • Indications Pulmonary embolism; Thromboembolism; Thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SAFE-AF
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 04 Jul 2012 Planned number of patients changed from 350 to 690 as reported in the European Clinical Trials Database record.
  • 04 Jul 2012 Bristol-Myers Squibb, Procter and Gamble, Sanofi added as associations as reported in the European Clinical Trials Database record.
  • 22 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top